JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Carcinomas of the paranasal sinuses: a study of sixty-six cases.

Cancer 1977 December
The therapy records of 66 patients with carcinomas of the paranasal sinuses were reviewed; primary carcinomas occurred in the maxillary sinus in 50 patients, the ethmoid sinus in 11 patients, the sphenoid sinus in 4 patients and the frontal sinus in 1 patient. The tumors of the maxillary sinus were staged retrospectively according to the American Joint Committee staging system recommended in 1976; 1 of 2 patients with T1, 5 of 11 patients with T2, 10 of 34 patients with T3 and 1 of 3 patients with T4 lesions showed no evidence of disease (NED) at 3 years. Combined high dose irradiation (6,000 rads in 6 weeks) followed by radical surgery in 4 to 6 weeks was well tolerated; this approach is recommended for the treatment of T1, T2, and selected T3-4 maxillary sinus lesions. Only 2 of 11 patients with ethmoid sinus lesions survived at 3 years.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app